Display options
Share it on

J Can Acad Child Adolesc Psychiatry. 2016;25(1):11-6. Epub 2016 Feb 01.

A Pilot Study of Citalopram Treatment in Preventing Relapse of Depressive Episode after Acute Treatment.

Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent

Amy Cheung, Anthony Levitt, Michael Cheng, Darcy Santor, Stan Kutcher, Elyse Dubo, E Jane Garland, Margaret Weiss, Alex Kiss

Affiliations

  1. University of Toronto, Toronto, Ontario; Sunnybrook Health Sciences Centre, Toronto, Ontario.
  2. University of Ottawa, Ottawa, Ontario; Children's Hospital of Eastern Ontario, Ottawa, Ontario.
  3. University of Ottawa, Ottawa, Ontario.
  4. Dalhousie University, Halifax, Nova Scotia.
  5. University of British Columbia, Vancouver, British Columbia.

PMID: 27047552 PMCID: PMC4791101

Abstract

PURPOSE: To examine the benefit of continuation treatment with citalopram in adolescents 13 to 18 years of age with major depression using a multi-site randomized placebo controlled discontinuation design.

METHODS: Subjects with depression who responded to open label treatment with citalopram in 12-week acute phase were randomized to continued treatment with citalopram or placebo for 24 weeks.

RESULTS: Twenty five subjects were randomized to either continued treatment with citalopram (n = 12) versus placebo (n = 13). Seventy-five percent of subjects on citalopram (75%) remained well as compared to placebo (62%). Time to relapse was compared between groups using the log rank test and was not found to be significantly different (χ(2)(1) = 0.35, P = 0.55). A Cox proportional hazards model including drug assignment (hazard ratio (HR = 0.51, 95% CI 0.11 to 2.36, P = 0.39), gender (HR = 0.58, 95% CI 0.14 to 2.37, P = 0.44), or HAM-score at entry to continuation phase (HR = 1.33, 95% CI 0.90 to 1.95, P = 0.95) was not significant.

CONCLUSION: Although we did not find statistically significant differences between citalopram and placebo, the findings suggest a possible benefit of continued treatment with citalopram over placebo. A larger clinical trial with adequate power is required to confirm or disconfirm these findings.

Keywords: adolescents; antidepressants; citalopram; depression

References

  1. Contemp Clin Trials. 2008 Nov;29(6):862-6 - PubMed
  2. JAMA. 2008 Feb 27;299(8):901-13 - PubMed
  3. JAMA. 2004 Aug 18;292(7):807-20 - PubMed
  4. Arch Gen Psychiatry. 1991 Sep;48(9):851-5 - PubMed
  5. J Am Acad Child Adolesc Psychiatry. 2009 Oct;48(10):987-96 - PubMed
  6. J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26 - PubMed
  7. Am J Psychiatry. 2008 Apr;165(4):459-67 - PubMed
  8. Ann Med. 2005;37(6):404-12 - PubMed
  9. J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 - PubMed
  10. Arch Gen Psychiatry. 1985 Jul;42(7):696-702 - PubMed
  11. Paediatr Drugs. 2005;7(4):203-17 - PubMed
  12. J Child Adolesc Psychopharmacol. 2008 Aug;18(4):389-94 - PubMed
  13. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 - PubMed
  14. J Clin Psychiatry. 1999 Dec;60(12):861-5 - PubMed

Publication Types